Chantix Pre-Marketing Trials Didn’t Include At Risk Groups

When Chantix, Pfizer’s so-called smoking cessation drug, was brought onto the market, it was touted as a good method to quit the habit. However, Pfizer’s pre-marketing trials didn’t include 44% of the smoking population-those with diagnosed mental disorders such as schizophrenics and alcoholics. This month, the FDA has reported 34 suicides among Chantix users. Increased suicides have not been reported with other smoking cessation drugs such as nicotine-replacement therapies like gum, lozenges or patches, or with bupropion, marketed by GlaxoSmithKline PLC as Zyban or Wellbutrin.